Palisade Bio, Inc. (PALI) Posts New PALI-2108 Data Backing Phase 2 in UC and CD

Palisade Bio (PALI) shares rose 9% after presenting early clinical data for PALI-2108, showing improvements in Crohn's disease patients. The Phase 1b study reported a 47.5% decrease in disease activity and 58.8% reduction in inflammation marker. The company is conducting further Phase 2 trials. PALI stock is currently at $1.46, up from its 52-week range of $1.32-$2.86.

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.

Palisade Bio (PALI) reported early Phase 1b data for PALI-2108, showing reductions in endoscopic activity and fecal calprotectin in Crohn's patients. Phase 2b UC trial is enrolling, and a Phase 2a Crohn's study is starting. The company noted these are early, open-label results.

Palisade Bio (PALI) reported that its experimental drug PALI-2108 showed a 58.8% reduction in a gut inflammation marker in five Crohn's disease patients after 14 days. The Phase 1b study also demonstrated endoscopic improvement and reduced intestinal inflammation. The company is advancing Phase 2b studies for ulcerative colitis and initiating a Phase 2a study for Crohn's disease.

HC Wainwright & Co. maintained a Buy rating on Palisade Bio, setting a $7 price target, implying a 340.3% upside from the Oct 12 close of $1.59. The firm cited promising clinical data for PALI-2108, showing 40% endoscopic response in 14 days, and a favorable safety profile.

Palisade Bio (PALI) presented clinical data on PALI-2108, an investigational drug for ulcerative colitis and Crohn's disease, at the ACG 2026 Annual Scientific Meeting. Two studies showed promising results, with all patients achieving clinical response in a 7-day ulcerative colitis study and a 47.5% mean reduction in a 14-day Crohn's disease study. The company is conducting a Phase 2 study in ulcerative colitis. PALI-2108 has not been approved for any indication.